Literature DB >> 6896541

Reduced plasma concentration of 1,25-dihydroxyvitamin D in children with moderate renal insufficiency.

A A Portale, B E Booth, H C Tsai, R C Morris.   

Abstract

We measured the plasma concentration of 1,25-dihydroxyvitamin D (1,25(OH)2D) in 39 children comprising three groups; eight with moderate renal insufficiency (GFR of 25 to 50 ml/min/1.73 M2, seven of whom had tubulointerstitial disease), eight with severe renal insufficiency (on chronic hemodialysis), and 23 healthy control subjects. The mean plasma concentration of 1,25-(OH)2D was reduced by some 40% (P less than 0.002) in the children with moderate renal insufficiency, and by some 80% (P less than 0.001) in the children with severe renal insufficiency. In the children with moderate renal insufficiency, the reduced concentration of 1,25-(OH)2D was associated with increased serum concentrations of immunoreactive parathyroid hormone (iPTH) and reduced serum concentrations of 1,25-(OH)2D was associated with increased serum concentrations of immunoreactive parathyroid hormone (iPTH) and reduced serum concentrations of calcium and phosphorus. When analyzed over the range of renal function from normal through severely impaired, values of iPTH correlate inversely and significantly with those of 1,25-(OH)2D. Growth was impaired in four of the eight children with moderate renal insufficiency. The results of the current study suggest that in children with moderate renal insufficiency, a reduction in the renal synthesis and in the plasma concentration of 1,25-(OH)2D may be important pathogenetic events in disordered metabolism of calcium and phosphorus, including secondary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6896541     DOI: 10.1038/ki.1982.70

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

1.  Recent developments in vitamin D metabolism and its clinical application for renal disease.

Authors:  R W Chesney
Journal:  Indian J Pediatr       Date:  1988 Jul-Aug       Impact factor: 1.967

2.  Disordered FGF23 and mineral metabolism in children with CKD.

Authors:  Anthony A Portale; Myles Wolf; Harald Jüppner; Shari Messinger; Juhi Kumar; Katherine Wesseling-Perry; George J Schwartz; Susan L Furth; Bradley A Warady; Isidro B Salusky
Journal:  Clin J Am Soc Nephrol       Date:  2013-12-05       Impact factor: 8.237

Review 3.  Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window.

Authors:  Uwe Querfeld; Robert H Mak
Journal:  Pediatr Nephrol       Date:  2010-06-22       Impact factor: 3.714

4.  Effect of vitamin D on growth cartilage cell proliferation in vitro.

Authors:  G Klaus; R Meinhold-Heerlein; P Milde; E Ritz; O Mehls
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

5.  Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.

Authors:  A A Portale; B E Booth; B P Halloran; R C Morris
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

Review 6.  Bone and mineral disorders in pre-dialysis CKD.

Authors:  Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Int Urol Nephrol       Date:  2008       Impact factor: 2.370

Review 7.  Mineral metabolism and bone abnormalities in children with chronic renal failure.

Authors:  Cheryl P Sanchez
Journal:  Rev Endocr Metab Disord       Date:  2008-01-04       Impact factor: 6.514

Review 8.  Recent advances and controversies in childhood renal osteodystrophy.

Authors:  O Mehls; I B Salusky
Journal:  Pediatr Nephrol       Date:  1987-04       Impact factor: 3.714

9.  Vitamin D metabolite profiles in moderate renal insufficiency of childhood.

Authors:  A Taylor; M E Norman
Journal:  Pediatr Nephrol       Date:  1988-10       Impact factor: 3.714

10.  Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans.

Authors:  A A Portale; B P Halloran; M M Murphy; R C Morris
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.